Ann: VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21, page-321

Fyi

Cohort 1 (group 1A and 1B) study is finished

Cohort 2 (group 2A) study finishes on Monday 8th March
Cohort 2 (group 2B) starts today and finishes 16th March
Cohort 2 (group 2C) starts next Monday and finishes 23rd March

I have been told by investor relations "it is progressing well"

This means no adverse events

Looking forward to viraleze being sold globally........beginning in EU and UK jurisdictions

Which brings me to the next comment..........

Please make note of the wording from the three announcements

Quarterly Cashflow and Activities Report announcement (29 January 2021)

Launch preparations and commercial activities are advancing well, including discussions with pharmacy chains, B2B customers, and online platforms. Licensing discussions are continuing in parallel.

VIRALEZE™ antiviral nasal spray registered in Europe announcement (23 February 2021)


In parallel with the consumer roll-out of VIRALEZE™, Starpharma is also progressing discussions with B2B customers (e.g. aged care, healthcare, travel providers, etc.) and potential partners

Starpharma is undertaking discussions with B2B customers (e.g. aged care, health care, travel providers, etc.), as well as with potential commercial partners seeking sales and marketing rights


Starpharma Interim Report and Half-Year Financial Results announcement (25 February 2021)

the sentence below was repeated twice in the report


Licensing discussions have also progressed in parallel with launch preparations for certain jurisdictions.
Licensing discussions have also progressed in parallel with launch preparations for certain jurisdictions.

The Company is also pursuing pharmacy distribution, business-to-business opportunities and potentially licencing for certain jurisdictions.


I wonder who the potential partner/s are........and in what jurisdictions......hopefully it is UK and EU